Broadview Ventures
VC Fund
Boston, United States
Broadview Ventures is a VC fund in Boston focused on Health Care and Biotechnology. Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.The FoundationLeducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.
- Total investments:
- 85
- Last investment:
- Lead investor:
- 27%
Last updated:
For AI agents: llms.txt
Industries Broadview Ventures invests in
Stages Broadview Ventures invests in
Countries Broadview Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Seed
- $1M–$18M
- Series A
- $1M–$20M
- Series B
- $7M–$45M
Investment Focus
Industry
- Health Care 37 (44%)
- Biotechnology 35 (41%)
- Medical Device 24 (28%)
- Therapeutics 20 (24%)
- Medical 13 (15%)
Stage
- Series A 22 (26%)
- Seed 14 (16%)
- Series B 13 (15%)
- Debt Financing 11 (13%)
- Funding Round 5 (6%)
Country
- United States 41 (48%)
- Switzerland 3 (4%)
- Canada 2 (2%)
- Israel 2 (2%)
- Denmark 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Benjamin Kreitman
Principal
|
Principal | Total investments: 5 | Find email | |
Christopher de Souza
Director
|
Director | Total investments: 11 | Find email | |
Daniel Gottlieb
Director
|
Director | Total investments: 1 | Find email | |
Maria Berkman
Director
|
Director | Total investments: 21 | Find email | |
Nichole Schiffer
Director of Operations
|
Director of Operations | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Mosanna is a Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach. | $80M / Series A / Jun 09, 2025 | ||
| Relief Cardiovascular is an inQB8 medical technologies portfolio company developing a revolutionary smart implant to decongest heart failure patients. | $12M / Series A / Jan 08, 2025 | ||
| Alveron Pharma develops treatment for hemorrhagic stroke, a severe unmet medical need. Alveron’s drug OKL-1111 strongly reduces hematoma expansion in a mouse model of intracranial hemorrhage. As an injection solution that is ready to use, OKL-1111 is being developed to do away with a laborious pre-treatment process. | $5.3M / Seed / Dec 06, 2024 | ||
| Aria CV was founded in 2010 by Drs. John Scandurra and Karl Vollmers, formerly Fellows at the University of Minnesota’s Medical Devices Center. Aria has an exclusive license to certain patents from the University of Minnesota. Aria CV’s device has the potential to improve outcomes by reducing the workload on the right side of the heart. | Series B / Sep 30, 2024 | ||
| CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients. | $48.5M / Series B / Sep 10, 2024 | ||
| XII Medical is a medical device developer company. It develops a minimally invasive outpatient technology for the treatment of obstructive sleep apnea. | $45M / Series B / Aug 21, 2024 | ||
| CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation | $16M / Series B / Aug 07, 2024 | ||
| IsomAb evaluate and develop isoform specific antibodies to treat disease. | $9.5M / Seed / Feb 20, 2024 | ||
| Cardiosense offers a physiological waveform AI platform to develop predictive biomarkers for the detection and treatment of disease. Its platform leverages multi-modal sensors and industry-leading AI to develop predictive biomarkers for the detection and treatment of disease. | $15.1M / Series A / Dec 08, 2022 | ||
Nyra Medical
|
MitraPlug has created a catheter-plug technology for repairing a leaky mitral valve in the heart.This adjustable device needs only a two-inch surgical incision and can be inserted directly into the heart. Then the cardiologist can use the catheter to adjust the size and position of the plug to correct the leakage. When correctly fitted, thecatheter is removed, and the incision is closed, leaving only a small scar. | $20M / Series A / Nov 18, 2022 | |
| See all 85 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Broadview Ventures invest in?
Broadview Ventures invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Seed stage. Most of the 85 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Broadview Ventures's check size?
Broadview Ventures typically joins rounds of $1M–$18M at Seed, $1M–$20M at Series A and $7M–$45M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Broadview Ventures participates in.
How do I contact Broadview Ventures?
Public channels for Broadview Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Broadview Ventures?
The team at Broadview Ventures includes Benjamin Kreitman (Principal), Christopher de Souza (Director) and Daniel Gottlieb (Director), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
